Regenaxis Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies to regenerate myelin and restore function in demyelinating diseases of the central nervous system. With a novel therapeutic approach targeting the biological mechanisms of remyelination, we aim to address a critical unmet need in neurology and unlock new therapeutic opportunities in neurodegeneration.
| Employees | 2 (1 on RocketReach) |
| Founded | 2025 |
| Industry | Biotechnology Research |
Looking for a particular Regenaxis Therapeutics employee's phone or email?
Nabil Osmani is the CEO and Co-founder of Regenaxis Therapeutics.
1 people are employed at Regenaxis Therapeutics.